Lung Cancer Research Foundation Recognizes Remarkable Contributions
The Lung Cancer Research Foundation (LCRF) is excited to announce its honorees for the upcoming Evening of Innovation gala, including prominent figures in the field of lung cancer research. Among this year’s honorees are Raymond E. Chalmé and Dr. Joan H. Schiller, MD, both celebrated for their significant contributions to the advancement of lung cancer research and support for patients.
Raymond E. Chalmé: A Beacon of Hope
Raymond E. Chalmé has served as a dedicated member of LCRF's board for nearly two decades. His unwavering commitment has profoundly influenced lung cancer research and positively impacted countless patients. Chalmé, along with his family, founded Elliot's Legacy Kites for a Cure, an annual event that honors his late father and raises essential funds for research. Over 18 years, this initiative has successfully generated over $8 million, facilitating nearly $50 million in subsequent research funding.
"Ray's commitment to lung cancer research is immeasurable," stated Aubrey Rhodes, Executive Director of LCRF. His tireless efforts inspire many to share in the vision of finding a cure through proactive research initiatives.
Chalmé's Personal Journey
Reflecting on his journey, Mr. Chalmé expressed, "Being honored at this event means the world to me. It's incredible to see the progress in lung cancer research since we lost our dad. Knowing that we have contributed to helping people live longer is heartwarming.” His dedication emphasizes the importance of ongoing research and the collective commitment to fighting lung cancer.
Dr. Joan H. Schiller: A Pioneer in Lung Cancer Research
Dr. Joan H. Schiller, who will be receiving the prestigious Founders Award at the gala, is recognized for her lifetime achievements in facilitating lung cancer research. As the founder and president of Free to Breathe, Dr. Schiller has made significant strides in advocating for lung cancer patients and promoting research opportunities.
She has been an influential figure in the lung cancer community for over two decades, holding various roles within LCRF and its predecessor organizations. Dr. Schiller is not only well-published but also internationally acclaimed for her research and clinical practices, continuously striving to improve treatment shared through her advocacy.
A Strong Advocate for Patients
In her own words, Dr. Schiller stated, "I am truly honored to receive the Founders Award. Placing patients first has always been my priority, enabling me to contribute positively to lung cancer research alongside remarkable colleagues at LCRF." Her dedication is evident in her work, which constantly seeks to prioritize patient welfare and address the critical needs within the lung cancer community.
AstraZeneca: Supporting Innovation in Lung Cancer Research
This year's gala will also highlight AstraZeneca as the Corporate Honoree, celebrating their commitment to partnership in lung cancer advocacy and innovation. Nabil Chebab, US Medical Franchise Head for Lung Cancer at AstraZeneca, noted, "AstraZeneca is honored to be recognized as the Corporate Honoree. Supporting initiatives like this helps to bring hope and extend lives for those affected by lung cancer.” The confluence of industry and research exemplifies the broader movement toward improving outcomes for patients everywhere.
The Significance of the Evening of Innovation Gala
The Evening of Innovation gala is not just a celebration; it represents a pivotal moment in advancing lung cancer research. Scheduled to occur at Cipriani 25 Broadway, attendees will engage with inspiring stories and learn how they can contribute to the ongoing fight against lung cancer.
What Lies Ahead for Lung Cancer Research
As we look toward the future, the commitment of individuals like Raymond E. Chalmé and Dr. Joan H. Schiller, along with corporate partners like AstraZeneca, continues to pave the way for transformative advancements in lung cancer treatments. The incredible financial support mobilized through efforts like Elliot's Legacy Kites for a Cure will lead to breakthroughs that change the lives of patients facing lung cancer.
Frequently Asked Questions
What is the purpose of the Evening of Innovation gala?
The gala serves to honor significant contributions in lung cancer research and raise funds to support ongoing initiatives for innovation and improvement in patient care.
Who are the key honorees for this year's gala?
The primary honorees are Raymond E. Chalmé, who will be recognized for his advocacy and fundraising efforts, and Dr. Joan H. Schiller, who receives the Founders Award for her contributions to lung cancer research.
How has the Chalmé family influenced lung cancer research?
The Chalmé family has played a crucial role in fundraising, raising over $8 million through their Elliot's Legacy event, which supports research initiatives aimed at advancing treatment options.
What role does AstraZeneca play in lung cancer advocacy?
AstraZeneca contributes significantly by collaborating with advocacy organizations and supporting research initiatives, making them a key partner in improving outcomes for lung cancer patients.
How can people contribute to lung cancer research?
Individuals can participate by attending fundraising events, donating, and advocating for lung cancer research initiatives to enhance awareness about the condition and ongoing studies.
